Physician profile
Gregory James Wcisel
NPI 1033125927
$9,454.96
in general payments reported to CMS, 2019-2025
43 companies · $2,567 in 2025
The $2,567 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $898 · 2020: $372 · 2021: $434 · 2022: $760 · 2023: $1,533 · 2024: $2,891 · 2025: $2,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,857 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,857.28 |
| Education | $133.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,830.14 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,090.89 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Genzyme Corporation | $825.65 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $684.49 | 2023-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $559.90 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $483.74 | 2019-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $463.55 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $281.08 | 2023-2025 | Winrevair, Recarbrio, Zerbaxa |
| Novartis Pharmaceuticals Corporation | $241.06 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $240.68 | 2022-2025 | Glassia |
| Baxter Healthcare | $239.02 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Hospital Products INC. | $217.79 | 2021-2025 | Acthar |
| Jazz Pharmaceuticals INC. | $213.77 | 2020-2025 | |
| Actelion Pharmaceuticals US, INC. | $162.01 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Verona Pharma, INC. | $155.68 | 2025 | Ohtuvayre |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $148.64 | 2022-2025 | Xolair |
| Grifols USA, LLC | $142.07 | 2020-2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $117.32 | 2019-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $114.22 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $109.54 | 2019-2024 | Xarelto |
| Philips North America LLC | $97.45 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Pharming Healthcare, INC. | $94.94 | 2022-2023 | Ruconest |
| Harmony Biosciences LLC | $93.07 | 2021-2025 | Wakix |
| Paratek Pharmaceuticals, INC. | $83.92 | 2021-2023 | Nuzyra |
| Axsome Therapeutics, INC. | $80.62 | 2023-2024 | Sunosi |
| United Therapeutics Corporation | $77.45 | 2022-2025 | Tyvaso |
| Pfizer INC. | $69.73 | 2019-2022 | |
| Inspire Medical Systems, INC. | $63.79 | 2024-2025 | Inspire |
| Insmed, INC. | $60.00 | 2023-2025 | Arikayce |
| Electromed, INC. | $57.21 | 2019-2024 | Smartvest |
| Sunovion Pharmaceuticals INC. | $51.30 | 2020 | |
| Shionogi INC | $46.57 | 2023-2024 | Fetroja |
| Pulmonx Corporation | $44.19 | 2021-2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Mallinckrodt Enterprises LLC | $38.12 | 2019 | |
| Advanced Respiratory, INC | $32.35 | 2019-2021 | |
| Lilly USA, LLC | $27.95 | 2025 | Zepbound |
| Phadia US INC. | $19.59 | 2024 | Immunocap |
| Inogen, INC. | $19.20 | 2021 | |
| Viatris Specialty LLC | $17.32 | 2025 | Yupelri |
| Allergan, INC. | $16.30 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.81 | 2023 | Quviviq |
| Astellas Pharma US INC | $14.48 | 2019 | |
| Circassia INC. | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Wcisel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.